Want to join the conversation?
$ABBV adjusted R&D was 15.5% of sales, reflecting funding action supporting the pipeline and the impact of both Stemcentrx transaction and the Boehringer Ingelheim collaboration. Adjusted SG&A was 22.2% of the sales in 2Q16, down 290 BPs from the prior year. Adjusted operating margin was 43.9% of sales, down 30 BPs relative to 2Q15.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?